— Why it moved
Why AIM Stock Surged Today — May 27, 2026
AIM tied its Ampligen drug to the new Ebola emergency, and a sub-dollar float ran 40%+ before giving it all back.
## What moved it AIM announced what it called an "emerging Ebola opportunity" for Ampligen, leaning on the WHO emergency declaration around the Bundibugyo outbreak. It's a preparedness pitch, not a signed deal — but with Ebola names in play across biotech that day, the headline was enough to light a fuse under a beaten-down penny stock.
## The mechanics Everything about the setup is built for a fast spike. Sub-$0.50 price, a float under 8M shares, and a market cap around $6M. Add a topical outbreak theme and the tape does the rest. Turnover was massive relative to the company's size.
## Numbers - Cap: ~$6M / float: ~7.8M shares - Day volume: ~496M (~28x avg) - Prev close: $0.23 → gap +7% - 52w range: $0.21–$20.33
## Where it ended up Stock Pulse flagged it at 10:41 AM, $0.42. It ran to $0.60 by 12:06 PM, up 44% from the alert, then bled back the rest of the afternoon to close $0.41 — basically flat, down 2% versus the alert. A textbook morning pop and afternoon give-back.
## Reality check - The round-trip is the point: the whole gain was gone by the close. - Ampligen has been the perennial "next catalyst" story for years, and an Ebola tie-in is speculative preparedness, not revenue. - This explains why it moved. It is not a reason to own it.